New consortium consisting of researchers from six Dutch knowledge institutions, coordinated by the CNCR and Radboud UMC, has been awarded with a grant of 4 million euros from ZonMW, to develop new research methods to improve treatment for neurodevelopmental disorders.

Wiep Scheper talks about her research to Alzheimer’s in the latest podcast of Brainwave, listen to it here!

Alessandro Moro (CNCR-FGA) and colleagues identified the endocytic protein dynamin as a central regulator for neuromodulator secretion from dense core vesicles in mammalian neurons. This study is now published in Science Advances.

The global biopharmaceutical company UCB and an FGA team led by Ruud Toonen signed a 700k€ contract for joint research to develop new treatment strategies for genetic epilepsy syndromes.

Rhodé van Westen (CNCR-FGA) and colleagues identify Synaptotagmin-1 and Synaptotagmin-7 as redundant calcium sensors for neuromodulator secretion from dense core vesicles in mammalian neurons. This study is published in PNAS on April 28th.

CNCR/FGA is seeking applications for an Assistant Professor in RNA Biology and application in neuroscience, who will develop an independent research program to explore new directions in translation regulation, RNA stability or –transport.

The EM core facility at the VU campus has applied their long-standing experience of monolayer ultrastructural analysis to a different field, the analysis of mircoogranisms such as bacteria.

De “outreach” activiteiten van het team Molecular Neurodegeneration van Wiep Scheper zijn beloond door de KNAW met de toekenning van een award van het pilotfonds ‘Wetenschapscommunicatie door wetenschappers: Gewaardeerd’!

With this take-off grant Claudia Persoon will investigate the commercial potential of the human neuron cell models and imaging techniques developed at Amsterdam UMC and VU University in search of new treatments for brain disorders.

a young patient who carries a SYT1 mutation is the first to receive a mechanism-based treatment with the prescription of bumetanide, aiming to reverse excitation/inhibition disturbance